SCHEMBL3048490

SCHEMBL3048490

CN1CCN(c2nc3nonc3nc2Nc2cccc3ccccc23)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.60
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
ALOX15 P16050 1/20 0.52
ALDH1A1 P00352 3/20 0.48
CYP2C19 P33261 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
HRH4 Q9H3N8 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
RAB9A P51151 1/20 0.44
EPHX2 P34913 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3051668 0.87 LMNA (0.74) LMNAKMT2AMEN1ALDH1A1CYP2C19
SCHEMBL3040678 0.73 EPHX2 (0.56) LMNAKMT2AMEN1ALOX15ALDH1A1
SCHEMBL16941526 0.73 LMNA (0.67) LMNAKMT2AMEN1ALDH1A1CYP2C19
SCHEMBL15614697 0.72 LMNA (0.84) LMNAKMT2AMEN1ALDH1A1CYP2C19
SCHEMBL3045605 0.72 ALOX15 (1.00) LMNAKMT2AALOX15ALDH1A1CYP2C19
SCHEMBL3049443 0.67 MAPT (0.49) KMT2AMEN1ALOX15ALDH1A1SMN1; SMN2
SCHEMBL5533853 0.67 EPHX2 (0.45) KMT2AMEN1ALOX15ALDH1A1CYP2C19
SCHEMBL27738602 0.66 HRH4 (0.58) HRH4HTR3A
SCHEMBL22543322 0.65 LMNA (0.46) LMNAKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL20570269 0.65 TP53 (0.67) LMNAKMT2AMEN1ALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178754-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2012-07-12 US claimed
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2010-09-02 US claimed
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-05-21 US claimed
EP-1799689-A1 FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-06-27 EP claimed
WO-2006044402-A1 FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO claimed
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2010-09-02 US disclosed
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents CDC73, VHL, RB1 LMNA 1432/4885KMT2A 3960/4885MEN1 35/4885
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents CDC73, RB1, CA5A LMNA 1452/4885KMT2A 4211/4885MEN1 37/4885
US-20120178754-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents CDC73, VHL, RB1 LMNA 1432/4885KMT2A 3960/4885MEN1 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.